Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice

OBJECTIVE(S): Breast cancer is one of the most common cancers in the world and is on the increase. MUC1 and HER2 as tumor-associated antigens (TAAs) are abnormally expressed to some extent in 75–80% of breast cancers. In our present research, a novel chimeric MUC1-HER2 (HM) protein was designed and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gheybi, Elaheh, Salmanian, Ali Hatef, Fooladi, Abbas Ali Imani, Salimian, Jafar, Hosseini, Hamideh Mahmoodzadeh, Halabian, Raheleh, Amani, Jafar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776432/
https://www.ncbi.nlm.nih.gov/pubmed/29372033
http://dx.doi.org/10.22038/IJBMS.2017.25686.6335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776432/
https://www.ncbi.nlm.nih.gov/pubmed/29372033
http://dx.doi.org/10.22038/IJBMS.2017.25686.6335

Ejemplares similares